Trial Profile
An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze (Asparaginase Erwinia Chrysanthemi)/Erwinase (Crisantaspase) Administered Following Hypersensitivity to E. Coli Asparaginase in Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 22 Jun 2015
Price :
$35
*
At a glance
- Drugs Crisantaspase (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Pharmacokinetics
- Sponsors Jazz Pharmaceuticals plc
- 12 May 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 12 Jun 2014 New trial record